Financial Statements: ITR/DFP

Record Test Processing

Belo Horizonte, August 11,

2022 - Instituto Hermes Pardini S.A. ("IHP"), one of Brazil's largest Diagnostic Medicine companies, announces its operating and

financial results for the second quarter of 2022 (2Q22). Except where stated otherwise, information in this document is provided in local currency (real). The consolidated information of the Company is prepared in accordance with the accounting practices adopted in Brazil, based on the Brazilian Corporation Law and CVM regulations, as well as International Accounting Standard (IAS) 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB).

1

2Q22 Highlights

RECORD

Following are the results

of the second quarter of 2022.

It was precisely at the end of 2Q22 on June 30 - that we announced the most transformational M&A in the history of the Pardini Group: the business combination 1 with the Fleury Group. The companies understand that the combination of their businesses signifies an extraordinary opportunity to create value for their stakeholders by increasing the Company's competitive edge and accelerating its organic and inorganic growth. The Companies estimate that the Fleury and Hermes Pardini business combination will generate an increase in the annual EBITDA of the combined company of between R$160 million and R$190 million. The combined Company represents annual pro forma revenue of R$6 billion, 487 PSC units distributed across the country, leadership in L2L and over 20,000 employees.

Given its strong reputation, quality and reliability, the "Hermes Pardini" brand will be retained for at least 10 years from the effective consummation of the Business

Combination, in all the units where it is currently used and will be expanded to new units that may be opened by virtue of its growth.

We once again set a new volume record in the quarter, processing 41.1 million tests in 2Q22 (+19.9% vs. 2Q21), driven

by L2L from a record number of clients,

thanks to market share gains in the southern and northeastern regions of Brazil, and by PSC, mainly with the rollout of the growth project in São

Paulo. The acquisitions made in the last 12 months and new growth avenues also contributed significantly to this new volume record. Excluding COVID tests, growth in relation to 2Q21 was even higher (22.4%).

Despite the decline in COVID and Toxicological tests this quarter, we generated practically the same revenue as in 2Q21, due to the resumption of recurring exams, the positive effect of recent acquisitions and price adjustments. Gross revenue ex-COVID came to R$525.9 million in 2Q22, a record, growing 16.7% from 2Q21. Excluding COVID and Toxicology, growth is even higher at 26.6%.

Gross revenue from COVID tests came to R$32.7 million in the quarter (5.9% of consolidated sales), decreasing 70.3% from 2Q21.

Another highlight was the increase in revenue by R$51.0 million in the quarter due to the acquisitions made in 2021: Laboratório Paulo Azevedo, Laboratório APC, IACS and Clínica Dra. Odivânia.

Gross profit decreased 26.2% in 2Q22 vs. 2Q21, affected mainly by the sharp reduction in the volume of COVID and Toxicological tests (the latter due to the creation of the periodical toxicological test, which was a requirement in 2Q21), factors that increase the Company's margin.

The same effect reflected in EBITDA, which came to R$107.6 million in 2Q22, down 28.7% from 2Q21. EBITDA margin stood at 20.7% in 2Q22, as against 29.0% in 2Q21.

PATIENT SERVICE CENTERS (PSC)

In 2Q22, Patient Service Centers (PSC) registered 33.3% growth in gross revenue ex-COVID. Total gross revenue increased 15.6% from the same period last year. Performance of PSC ex- COVID was driven by the resumption of recurring exams (including imaging), ramp-up of new units in São Paulo and the acquisitions made since 2021. São Paulo once again performed remarkably, more than doubling its revenue in 2Q22 vs. 2Q21.

All units acquired from DaVita Serviços Médicos are already operating, with the following units opened this quarter: May: Mogi das Cruzes, Osasco, Guarulhos Esperança, Santa Cruz, Freguesia do Ó, Anália Franco, São Miguel Paulista, Tatuapé Tuiuti, Santo Amaro, Taboão da Serra, São Judas and Lapa; June: São Bernardo and Guarulhos.

The Hermes Pardini brand currently has 21 units in the state of São Paulo. Combined with IACS, the total comes to 37 units.

This means that competitors will gradually lose their accreditation to serve clients covered by the agreement with Amil signed in late 2021.

1 Transaction subject to approval from Brazil's antitrust agency CADE.

3

Still in São Paulo, the new units have

already been accredited by clients and we are confident about expanding the accreditation to other insurers and health plans operating in the region.

As such, the number of PSC units in

São Paulo at the end of 2Q22 was 600% higher than at the end of 2Q21, due to the addition of 32 units. Considering all brands, the Company

ended 2Q22 with 182 units in the

states of Minas Gerais, São Paulo, Goiás, Rio de Janeiro and Pará.

In Rio de Janeiro, after lengthy negotiations, we successfully re-

accredited our units with the main health plan in that region, which will take effect in 3Q22.

Moving on with the capture of synergies from the new acquisitions, in 2Q22, clinical analyses were added to Clínica de Imagem Dra. Odivânia and vaccines to Laboratório Paulo Azevedo (LPA) in Pará. In LPA, the Company is also optimizing its inputs and standardizing the service and call center structure, which was incorporated in Belo Horizonte,

LAB-TO-LAB

In 2Q22, L2L registered growth in

recurring revenue ex-COVID and ex-

Toxicology. Excluding COVID and Toxicological tests, revenue grew 21.1%. Excluding COVID tests, gross revenue grew 5.7% in 2Q22 vs. 2Q21.

Consolidated revenue decreased 11.7%. due to fewer toxicological tests, which in 2Q21 benefited from the demand created by the amendment to law that created the "periodical toxicological test", as well as the strong

comparison base of COVID tests.

Recurring business was healthy, reflecting the consolidated L2L volume, which increased 14.7% in 2Q22 vs. 2Q21 - the highest in Pardini's history. Excluding COVID and Toxicological tests, growth was 18.1%.

We achieved a record number of clients for a quarter, with the average volume per client increasing significantly by 10.6% in 2Q22 compared to 2Q21.

demonstrating the continuous gain

in market share, thanks to the

increase in outsourced laboratory tests by our clients.

Regionally, the strategy of increasing production in strategic geographies

has been leading to sharp growth in recurring businesses. In Solução (southern region), annual revenue excluding COVID and Toxicology increased by around 30%, and in Fortaleza (northeastern operation), expansion was over 27%.

The innovative revenue generating L2L fronts (Hospital Support and Pardis - Pardini Distribuidora) accounted for 6.7% of L2L gross revenue in 2Q22, up 120 bps from 1Q22.

Penetration in our client base increased, with 33% of our L2L client base making at least one purchase at Pardis.

We recently launched a new sales platform, developed in partnership with VTEX, which will enable us to implement a B2B marketplace. Soon we will have the first partner stores being opened to clients.

In Hospital Support, negotiations

are in an advanced stage of contractual formalization to acquire new operations.

TOXICOLOGY

Gross revenue from Toxicological exams came to R$22.8 million in 2Q22, down 57.3% from 2Q21, due to the strong comparison base of 2Q21, as already mentioned.

The strategic focus of the sales team on expansion resulted in market share gain in Toxicology this quarter, estimated at 160 bps.

Occupational Toxicology is currently transitioning to the Enterprise model at NTO. The transition of this specialized area will reduce costs and timeframes for test results, bringing it closer to the industrial model.